Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and United Therapeutics (NASDAQ:UTHR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
Profitability
This table compares Xenon Pharmaceuticals and United Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenon Pharmaceuticals | N/A | -43.98% | -41.72% |
| United Therapeutics | 41.56% | 20.18% | 17.98% |
Analyst Ratings
This is a summary of recent ratings and price targets for Xenon Pharmaceuticals and United Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenon Pharmaceuticals | 1 | 1 | 12 | 1 | 2.87 |
| United Therapeutics | 1 | 2 | 11 | 0 | 2.71 |
Insider & Institutional Ownership
95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Xenon Pharmaceuticals and United Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenon Pharmaceuticals | $7.50 million | 469.69 | -$345.91 million | ($4.74) | -7.69 |
| United Therapeutics | $3.18 billion | 7.40 | $1.33 billion | $27.95 | 19.65 |
United Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Xenon Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Summary
United Therapeutics beats Xenon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
